We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development.
- Authors
Haque, Inamul; Thapa, Pritam; Burns, Douglas M.; Zhou, Jianping; Sharma, Mukut; Sharma, Ram; Singh, Vikas
- Abstract
Epilepsy is one of the most prevalent and serious brain disorders and affects over 70 million people globally. Antiseizure medications (ASMs) relieve symptoms and prevent the occurrence of future seizures in epileptic patients but have a limited effect on epileptogenesis. Addressing the multifaceted nature of epileptogenesis and its association with the Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated neuroinflammation requires a comprehensive understanding of the underlying mechanisms of these medications for the development of targeted therapeutic strategies beyond conventional antiseizure treatments. Several types of NLRP3 inhibitors have been developed and their effect has been validated both in in vitro and in vivo models of epileptogenesis. In this review, we discuss the advances in understanding the regulatory mechanisms of NLRP3 activation as well as progress made, and challenges faced in the development of NLRP3 inhibitors for the treatment of epilepsy.
- Subjects
DRUG discovery; NLRP3 protein; DRUG development; INFLAMMASOMES; PEOPLE with epilepsy; SUDDEN death
- Publication
International Journal of Molecular Sciences, 2024, Vol 25, Issue 11, p6078
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms25116078